Attenuation of Diabetes-Induced Defects in Cardiac Sarcoplasmic Reticulum and Myofibrils by Propionyl L-Carnitine Therapy
5 affiliations
- 1Asper Clinical Research Institute, St. Boniface Hospital, Winnipeg, MB R2H 2A6, Canada
- 2Department of Food and Human Nutritional Sciences, Faculty of Agricultural and Food Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada
- 3Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB R2H 2A6, Canada
- 4Department of Physiology and Pathophysiology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0J9, Canada
- 5Center for Drug Discovery, BRIC-Translational Health Science and Technology Institute, Faridabad 121001, India
Abstract
Our previous work showed that treatment of diabetic rats with propionyl L-carnitine (PPLC), a metabolic intervention, improved cardiac function and depressed the occurrence of Ca2+-overload in addition to attenuating sarcolemmal defects in Na+-K+ ATPase, Na+-Ca2+ exchange and Ca2+/Mg2+-ecto ATPase activities. This study was undertaken to examine the efficacy of PPLC treatment on changes in sarcoplasmic reticulum (SR) Ca2+-uptake and Ca2+-stimulated ATPase as well as myofibril (MF) Ca2+-ATPase activities by employing male Sprague-Dawley rats injected with streptozotocin (65 mg/kg) for the induction of diabetes. Three days after inducing diabetes, diabetic rats were treated with or without PPLC (250 mg/kg/day) for 8 weeks. PPLC treatment was observed to improve cardiac function and attenuate depressions in both SR Ca2+-uptake and Ca2+-pump ATPase activities without affecting depressions in MF Ca2+-stimulated or Mg2+-ATPase activities as well as myosin Ca2+- or actin-stimulated ATPase activities in diabetic hearts. PPLC treatment also reduced the increased content of cardiac long-chain acylcarnitine as well as the plasma levels of free fatty acids and triglycerides without affecting the elevated levels of plasma glucose or depressed levels of plasma insulin in diabetic animals. The depression in cardiac carnitine content was corrected by PPLC treatment. Under in vitro conditions, palmitoyl L-carnitine (PMLC; a long-chain acylcarnitine) did not affect MF Ca2+-stimulated ATPase in the absence or presence of PPLC, whereas the inhibitory effect of PMLC on SR Ca2+-stimulated ATPase activities was antagonized by PPLC. These data suggest that the beneficial effects of PPLC in diabetic cardiomyopathy may be associated with attenuation of SR Ca2+-handling defects rather than with any action regarding depressed MF ATPase activity.
Related
- Oleoyl-L-carnitine regulates PPM1B through BIRC6, inducing tumor concomitant cardiac fibrosis
- Dried Urine Spots for Quantification of C0 (Free) Carnitine Excretion: A Validated Method for Follow-Up and Confirmatory Testing of Primary Carnitine Deficiency.
- Thrombophlebitis in an Adolescent Patient With Primary Carnitine Deficiency: A Case Report
- Exogenous carnitine can modulate oxaliplatin sensitivity in colorectal cancer cells in vitro
- γ-Butyrobetaine, L-carnitine and acylcarnitines and their association with incident atrial fibrillation among men and women with suspected chronic coronary syndrome.
BibTeX
@article{tappia2026attenuation,
title = {{Attenuation of Diabetes-Induced Defects in Cardiac Sarcoplasmic Reticulum and Myofibrils by Propionyl L-Carnitine Therapy}},
author = {Paramjit S. Tappia and Jaideep K. Gill and Vijayan Elimban and Ruchi Tandon and Naranjan S. Dhalla},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219512},
url = {https://www.mdpi.com/1422-0067/27/21/9512},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Attenuation of Diabetes-Induced Defects in Cardiac Sarcoplasmic Reticulum and Myofibrils by Propionyl L-Carnitine Therapy
AU - Paramjit S. Tappia
AU - Jaideep K. Gill
AU - Vijayan Elimban
AU - Ruchi Tandon
AU - Naranjan S. Dhalla
PY - 2026
DA - 2026/10/24
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219512
UR - https://www.mdpi.com/1422-0067/27/21/9512
AB - Our previous work showed that treatment of diabetic rats with propionyl L-carnitine (PPLC), a metabolic intervention, improved cardiac function and depressed the occurrence of Ca2+-overload in addition to attenuating sarcolemmal defects in Na+-K+ ATPase, Na+-Ca2+ exchange and Ca2+/Mg2+-ecto ATPase activities. This study was undertaken to examine the efficacy of PPLC treatment on changes in sarcoplasmic reticulum (SR) Ca2+-uptake and Ca2+-stimulated ATPase as well as myofibril (MF) Ca2+-ATPase activities by employing male Sprague-Dawley rats injected with streptozotocin (65 mg/kg) for the induction of diabetes. Three days after inducing diabetes, diabetic rats were treated with or without PPLC (250 mg/kg/day) for 8 weeks. PPLC treatment was observed to improve cardiac function and attenuate depressions in both SR Ca2+-uptake and Ca2+-pump ATPase activities without affecting depressions in MF Ca2+-stimulated or Mg2+-ATPase activities as well as myosin Ca2+- or actin-stimulated ATPase activities in diabetic hearts. PPLC treatment also reduced the increased content of cardiac long-chain acylcarnitine as well as the plasma levels of free fatty acids and triglycerides without affecting the elevated levels of plasma glucose or depressed levels of plasma insulin in diabetic animals. The depression in cardiac carnitine content was corrected by PPLC treatment. Under in vitro conditions, palmitoyl L-carnitine (PMLC; a long-chain acylcarnitine) did not affect MF Ca2+-stimulated ATPase in the absence or presence of PPLC, whereas the inhibitory effect of PMLC on SR Ca2+-stimulated ATPase activities was antagonized by PPLC. These data suggest that the beneficial effects of PPLC in diabetic cardiomyopathy may be associated with attenuation of SR Ca2+-handling defects rather than with any action regarding depressed MF ATPase activity.
SN - 1422-0067
ER -